Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 184
Filter
1.
J Clin Endocrinol Metab ; 106(10): e3865-e3880, 2021 09 27.
Article in English | MEDLINE | ID: mdl-34143883

ABSTRACT

CONTEXT: 11ß-hydroxysteroid dehydrogenase type 1 (11ß-HSD1) inhibitors demonstrate antimetabolic and antisarcopenic effects in Cushing's syndrome (CS) and autonomous cortisol secretion (ACS) patients. OBJECTIVE: To confirm the efficacy and safety of S-707106 (11ß-HSD1 inhibitor) administered to CS and ACS patients. DESIGN: A 24-week single-center, open-label, single-arm, dose-escalation, investigator-initiated clinical trial on a database. SETTING: Kyushu University Hospital, Kurume University Hospital, and related facilities. PATIENTS: Sixteen patients with inoperable or recurrent CS and ACS, with mildly impaired glucose tolerance. INTERVENTION: Oral administration of 200 mg S-707106 after dinner, daily, for 24 weeks. In patients with insufficient improvement in oral glucose tolerance test results at 12 weeks, an escalated dose of S-707106 (200 mg twice daily) was administered for the residual 12 weeks. MAIN OUTCOME MEASURES: The rate of participants responding to glucose tolerance impairment, defined as those showing a 25% reduction in the area under the curve (AUC) of plasma glucose during the 75-g oral glucose tolerance test at 24 weeks. RESULTS: S-707106 administration could not achieve the primary endpoint of this clinical trial (>20% of responsive participants). AUC glucose decreased by -7.1% [SD, 14.8 (90% CI -14.8 to -1.0), P = 0.033] and -2.7% [14.5 (-10.2 to 3.4), P = 0.18] at 12 and 24 weeks, respectively. S-707106 administration decreased AUC glucose significantly in participants with a high body mass index. Body fat percentage decreased by -2.5% [1.7 (-3.3 to -1.8), P < 0.001] and body muscle percentage increased by 2.4% [1.6 (1.7 to 3.1), P < 0.001]. CONCLUSIONS: S-707106 is an effective insulin sensitizer and antisarcopenic and antiobesity medication for these patients.


Subject(s)
11-beta-Hydroxysteroid Dehydrogenase Type 1/antagonists & inhibitors , Cushing Syndrome/drug therapy , Enzyme Inhibitors/therapeutic use , Hydrocortisone/metabolism , Organic Chemicals/therapeutic use , Adult , Aged , Aged, 80 and over , Asymptomatic Diseases , Cushing Syndrome/metabolism , Databases, Factual , Female , Humans , Japan , Male , Middle Aged , Paraneoplastic Endocrine Syndromes/drug therapy , Paraneoplastic Endocrine Syndromes/metabolism , Registries
2.
J Clin Endocrinol Metab ; 105(5)2020 05 01.
Article in English | MEDLINE | ID: mdl-32154561

ABSTRACT

CONTEXT: Several studies have reported increased risk of fragility fractures in patients with mild autonomous cortisol secretion (MACS), discordant to the degree of bone density deterioration. OBJECTIVE: To evaluate the effect of MACS on bone metabolism in patients with adrenal adenomas. DESIGN: Cross-sectional study with prospective enrollment, 2014-2019. SETTING: Referral center. PATIENTS: 213 patients with adrenal adenomas: 22 Cushing syndrome (CS), 92 MACS and 99 nonfunctioning adrenal tumors (NFAT). MAIN OUTCOME MEASURES: Osteocalcin, procollagen I intact N-terminal (PINP), C-terminal telopeptide (CTX), sclerostin. RESULTS: Patients with CS demonstrated lower markers of bone formation compared with patients with MACS and NFAT (CS vs MACS vs NFAT: mean osteocalcin 14.8 vs 20.1 vs 21.3 ng/mL [P < 0.0001]; mean PINP 34.8 vs 48.7 vs 48.5 µg/L [P = 0.003]). Severity of cortisol excess was inversely associated with sclerostin (CS vs MACS vs NFAT: mean sclerostin 419 vs 538 vs 624 ng/L, [P < 0.0001]). In a multivariable model of age, sex, body mass index, cortisol, and bone turnover markers, sclerostin was a significant predictor of low bone mass in patients with MACS (OR 0.63 [CI 95%, 0.40-0.98] for each 100 ng/L of sclerostin increase).After adrenalectomy, osteocalcin, CTX, and sclerostin increased by a mean difference of 6.3 ng/mL, 0.12 ng/mL, and 171 pg/mL (P = 0.02 for all), respectively. CONCLUSIONS: Lower sclerostin level in patients with MACS reflects a reduction in osteocyte function or number associated with exposure to chronic cortisol excess. Increase in bone turnover markers after adrenalectomy suggests restoration of favorable bone metabolism.


Subject(s)
Biomarkers/blood , Bone and Bones/metabolism , Hydrocortisone/metabolism , Paraneoplastic Endocrine Syndromes/metabolism , Adaptor Proteins, Signal Transducing/blood , Adenoma/metabolism , Adenoma/pathology , Adolescent , Adrenal Gland Neoplasms/metabolism , Adrenal Gland Neoplasms/pathology , Adult , Biomarkers/analysis , Bone Remodeling/physiology , Collagen Type I/blood , Cross-Sectional Studies , Cushing Syndrome/metabolism , Female , Humans , Hydrocortisone/blood , Male , Middle Aged , Minnesota , Osteocalcin/blood , Peptides/blood , Procollagen/blood , Severity of Illness Index , Young Adult
4.
Endocr J ; 65(2): 245-252, 2018 Feb 26.
Article in English | MEDLINE | ID: mdl-29225207

ABSTRACT

Primary hyperparathyroidism is the most common hormonal manifestation associated with multiple endocrine neoplasia 1 (MEN1). It is generally caused by parathyroid hyperplasia, and parathyroid carcinoma is rare. Here, we report a case of MEN1 with parathyroid carcinoma in two parathyroid glands causing primary hyperparathyroidism. A 40-year-old man with primary hyperparathyroidism due to MEN1 underwent a total parathyroidectomy. His corrected calcium and intact PTH (i-PTH) serum levels were 10.8 mg/dL and 203 pg/mL, respectively. Although three glands were successfully removed, the left upper parathyroid gland could not be detected. Since the right lower parathyroid lesion had invaded into the thyroid, right lobectomy was performed. A portion of the left lower parathyroid tissue was transplanted into his forearm. The histological findings of the left lower and the right upper parathyroid glands were consistent with hyperplasia while that of the right lower parathyroid gland was parathyroid carcinoma. Since the post-surgical i-PTH levels remained high, the intrathyroidal lesion of the left lobe, which was initally diagnosed as an adenomatous nodule, was suspected to contain parathyroid tumor. A fine needle aspiration of the tumor revealed a high concentration of i-PTH. One week after the first surgery, a left thyroid lobectomy was performed. The pathological diagnosis of the tumor was parathyroid carcinoma. After the surgery, calcium and i-PTH levels were normal. Although it is rare, parathyroid carcinoma should be considered as a cause of hyperparathyroidism in MEN1 patients. Since it is difficult to diagnose parathyroid carcinoma before surgery, intraoperative findings are important for the appropriate treatment.


Subject(s)
Choristoma/diagnosis , Hyperparathyroidism, Primary/diagnosis , Multiple Endocrine Neoplasia Type 1/diagnosis , Paraneoplastic Endocrine Syndromes/diagnosis , Parathyroid Glands , Parathyroid Neoplasms/diagnosis , Thyroid Neoplasms/diagnosis , Adult , Choristoma/complications , Choristoma/metabolism , Humans , Hyperparathyroidism, Primary/etiology , Male , Multiple Endocrine Neoplasia Type 1/complications , Multiple Endocrine Neoplasia Type 1/pathology , Neoplasms, Multiple Primary/diagnosis , Neoplasms, Multiple Primary/metabolism , Neoplasms, Multiple Primary/pathology , Pancreatic Neoplasms/complications , Pancreatic Neoplasms/diagnosis , Pancreatic Neoplasms/pathology , Paraneoplastic Endocrine Syndromes/complications , Paraneoplastic Endocrine Syndromes/metabolism , Parathyroid Hormone/metabolism , Parathyroid Neoplasms/pathology , Thyroid Neoplasms/metabolism , Thyroid Neoplasms/secondary
5.
J Transl Med ; 15(1): 238, 2017 Nov 25.
Article in English | MEDLINE | ID: mdl-29178939

ABSTRACT

BACKGROUND AND AIMS: Intrahepatic cholangiocarcinoma (ICC) is an aggressive tumor with a high fatality rate. It was recently found that parathyroid hormone-like hormone (PTHLH) was frequently overexpressed in ICC compared with non-tumor tissue. This study aimed to elucidate the underlying mechanisms of PTHLH in ICC development. METHODS: The CCK-8 assay, colony formation assays, flow cytometry and a xenograft model were used to examine the role of PTHLH in ICC cells proliferation. Immunohistochemistry (IHC) and western blot assays were used to detect target proteins. Luciferase reporter, chromatin immunoprecipitation (ChIP) and DNA pull-down assays were used to verify the transcription regulation of activating transcription factor-2 (ATF2). RESULTS: PTHLH was significantly upregulated in ICC compared with adjacent and normal tissues. Upregulation of PTHLH indicated a poor pathological differentiation and intrahepatic metastasis. Functional study demonstrated that PTHLH silencing markedly suppressed ICC cells growth, while specific overexpression of PTHLH has the opposite effect. Mechanistically, secreted PTHLH could promote ICC cell growth by activating extracellular signal-related kinase (ERK) and c-Jun N-terminal kinase (JNK) signaling pathways, and subsequently upregulated ATF2 and cyclinD1 expression. Further study found that the promoter activity of PTHLH were negatively regulated by ATF2, indicating that a negative feedback loop exists. CONCLUSIONS: Our findings demonstrated that the ICC-secreted PTHLH plays a characteristic growth-promoting role through activating the canonical ERK/JNK-ATF2-cyclinD1 signaling pathways in ICC development. We identified a negative feedback loop formed by ATF2 and PTHLH. In this study, we explored the therapeutic implication for ICC patients.


Subject(s)
Bile Duct Neoplasms/metabolism , Bile Duct Neoplasms/pathology , Cell Proliferation , Cholangiocarcinoma/metabolism , Cholangiocarcinoma/pathology , Parathyroid Hormone-Related Protein/metabolism , Activating Transcription Factor 2/metabolism , Adult , Aged , Aged, 80 and over , Animals , Autocrine Communication/physiology , Bile Duct Neoplasms/genetics , Bile Ducts, Intrahepatic/metabolism , Bile Ducts, Intrahepatic/pathology , Cell Line, Tumor , Cell Proliferation/drug effects , Cell Proliferation/genetics , Cholangiocarcinoma/genetics , Cyclin D1/metabolism , Extracellular Signal-Regulated MAP Kinases/metabolism , Female , Gene Expression Regulation, Neoplastic/drug effects , Humans , JNK Mitogen-Activated Protein Kinases/metabolism , Male , Mice , Mice, Inbred BALB C , Mice, Nude , Middle Aged , Paraneoplastic Endocrine Syndromes/genetics , Paraneoplastic Endocrine Syndromes/metabolism , Paraneoplastic Endocrine Syndromes/pathology , Parathyroid Hormone-Related Protein/pharmacology , Parathyroid Hormone-Related Protein/physiology , Signal Transduction/drug effects
6.
Endocr Relat Cancer ; 24(6): R173-R190, 2017 06.
Article in English | MEDLINE | ID: mdl-28341725

ABSTRACT

The majority of neoplasms are responsible for symptoms caused by mass effects to surrounding tissues and/or through the development of metastases. However, occasionally neoplasms, with or without endocrine differentiation, acquire the ability to secrete a variety of bioactive substances or induce immune cross-reactivity with the normal tissues that can lead to the development of characteristic clinical syndromes. These syndromes are named endocrine paraneoplastic syndromes when the specific secretory components (hormones, peptides or cytokines) are unrelated to the anticipated tissue or organ of origin. Endocrine paraneoplastic syndromes can complicate the patient's clinical course, response to treatment, impact prognosis and even be confused as metastatic spread. These syndromes can precede, occur concomitantly or present at a later stage of tumour development, and along with the secreted substances constitute the biological 'fingerprint' of the tumour. Their detection can facilitate early diagnosis of the underlying neoplasia, monitor response to treatment and/or detect early recurrences following successful initial management. Although when associated with tumours of low malignant potential they usually do not affect long-term outcome, in cases of highly malignant tumours, endocrine paraneoplastic syndromes are usually associated with poorer survival outcomes. Recent medical advances have not only improved our understanding of paraneoplastic syndrome pathogenesis in general but also enhanced their diagnosis and treatment. Yet, given the rarity of endocrine paraneoplastic syndromes, there is a paucity of prospective clinical trials to guide management. The development of well-designed prospective multicentre trials remains a priority in the field in order to fully characterise these syndromes and provide evidence-based diagnostic and therapeutic protocols.


Subject(s)
Paraneoplastic Endocrine Syndromes , Animals , Humans , Neoplasms/metabolism , Paraneoplastic Endocrine Syndromes/diagnosis , Paraneoplastic Endocrine Syndromes/etiology , Paraneoplastic Endocrine Syndromes/metabolism , Peptide Hormones/metabolism
7.
BMC Endocr Disord ; 15: 6, 2015 Feb 27.
Article in English | MEDLINE | ID: mdl-25887139

ABSTRACT

BACKGROUND: The prevailing view that advocates long-term hormonal follow-up of adrenal incidentalomas is currently under debate. The purpose of the present study was to examine all adrenal incidentalomas presented during five years to a single centre. We hypothesized that 24-month biochemical follow-up in patients with an initial normal screening would fail to increase the sensitivity in finding hormone producing tumours. METHODS: The present study is a retrospective register based cohort study of 194 patients referred to the Department of Endocrinology at Södersjukhuset between the years 2006-2010. Computerized medical records were used to find and extract information on patients with newly discovered adrenal incidentalomas. The sensitivity, specificity, positive predictive value and negative predictive value were calculated to evaluate the validity of an initial normal screening when used to identify individuals with hormone producing tumours. RESULTS: Of the incidentalomas 94% consisted of benign, non-functioning tumours. Three patients were diagnosed with cortisol hypersecretion and one with pheochromocytoma. The sensitivity, specificity, positive predictive value and negative predictive value of an initial complete negative screening to predict a hormone producing tumour were 100%, 63%, 12% and 100%, respectively. CONCLUSION: Patients with an initially normal hormonal screening may not need further biochemical follow-up.


Subject(s)
Adrenal Gland Neoplasms/diagnosis , Biomarkers/analysis , Monitoring, Physiologic/methods , Adrenal Gland Neoplasms/blood , Adrenal Gland Neoplasms/epidemiology , Adrenal Gland Neoplasms/metabolism , Aged , Biomarkers/blood , Female , Follow-Up Studies , Humans , Male , Medical Futility , Middle Aged , Paraneoplastic Endocrine Syndromes/diagnosis , Paraneoplastic Endocrine Syndromes/epidemiology , Paraneoplastic Endocrine Syndromes/metabolism , Pheochromocytoma/diagnosis , Pheochromocytoma/epidemiology , Pheochromocytoma/metabolism , Predictive Value of Tests , Prognosis , Registries , Retrospective Studies , Sensitivity and Specificity
9.
J Clin Endocrinol Metab ; 99(4): E674-82, 2014 Apr.
Article in English | MEDLINE | ID: mdl-24285684

ABSTRACT

CONTEXT: The molecular mechanisms of primary aldosteronism, a common cause of human hypertension, are unknown, but alterations of K(+) channels can play a key role. OBJECTIVE: The objective of the study was to investigate the following: 1) the expression of the Twik-related acid-sensitive K(+) channels (TASK) in aldosterone producing adenomas (APAs); 2) the role of TASK-2 in aldosterone synthesis; and 3) the determinants of TASK-2-blunted expression in APAs. DESIGN: We analyzed the transcriptome and the microRNA profiles of 32 consecutive APAs and investigated the protein expression and localization of TASK-2 in APA and adrenocortical cell lines (H295R and HAC15) using immunoblotting and confocal microscopy. The functional effect of TASK-2 blunted activity caused by a dominant-negative mutation on steroidogenic enzymes, and aldosterone production was also assessed. TASK-2 regulation by selected microRNA was studied by a luciferase assay. RESULTS: TASK-2 was consistently less expressed at the transcript and protein levels in APAs than in the normal human adrenal cortex. H295R cell transfection with a TASK-2 dominant-negative mutant construct significantly increased the aldosterone production by 153% and the gene expression of aldosterone synthase (CYP11B2, gene expression fold change 3.1 vs control, P < .05) and the steroidogenic acute regulatory protein (gene expression fold change 1.8 vs control, P < .05). Two microRNAs, hsa-miR-23 and hsa-miR-34, were found to decrease the TASK-2 expression by binding to the 3' untranslated region of the TASK-2 gene. CONCLUSIONS: The TASK-2 channel lower expression represents a hallmark of APA and is associated with a higher expression of hsa-miR-23 and hsa-miR-34. The ensuing blunted TASK-2 activity increased the production of aldosterone in vitro and the expression of steroidogenic acute regulatory protein and CYP11B2. Hence, the lower expression of TASK-2 channel in APA cells can explain high aldosterone secretion in human primary aldosteronism despite the suppression of angiotensin II, hypertension, and hypokalemia.


Subject(s)
Adenoma/metabolism , Adrenal Cortex Neoplasms/metabolism , Aldosterone/metabolism , Hyperaldosteronism/genetics , Potassium Channels, Tandem Pore Domain/genetics , Adenoma/genetics , Adrenal Cortex Neoplasms/genetics , Cells, Cultured , Down-Regulation , Gene Expression Profiling , Gene Expression Regulation, Neoplastic , HEK293 Cells , Humans , Hyperaldosteronism/metabolism , Microarray Analysis , Paraneoplastic Endocrine Syndromes/genetics , Paraneoplastic Endocrine Syndromes/metabolism
10.
Rev Pneumol Clin ; 69(5): 298-301, 2013 Oct.
Article in French | MEDLINE | ID: mdl-24035551

ABSTRACT

INTRODUCTION: The inadequate secretion of ß-human chorionic gonadotropin (ß-HCG) during non-small cell lung cancer (NSCLC) is rare and quite ignored. The dosage of ß-HCG is probably not systematically realized in women who are in age of pregnancy and who need chemotherapy (CT) despite the descriptions of cases of prescription of CT against lung cancer in women who were pregnant. The incidence of NSCLC cancer is increasing and the risk to prescribe a CT in a woman who is pregnant is also increasing. CASES REPORTS: We describe the cases of two women and one man who had an augmentation of the ß-HCG plasmatic level before the prescription of CT against lung cancer. In women, the differential diagnostic between inadequate secretion of ß-HCG and pregnancy has been a problem. CONCLUSION: The inadequate secretion of ß-HCG during NSCLC is probably not so rare. The dosage of this hormone before each infusion of CT should be systematic to avoid the realization of CT during pregnancy. This raises the question of the method for differential diagnostic between pregnancy and inadequate secretion of ß-HCG in young women who suffer from NSCLC, especially when a small level of ß-HCG is measured.


Subject(s)
Carcinoma, Non-Small-Cell Lung/diagnosis , Chorionic Gonadotropin, beta Subunit, Human/metabolism , Lung Neoplasms/diagnosis , Paraneoplastic Endocrine Syndromes/diagnosis , Carcinoma, Non-Small-Cell Lung/metabolism , Diagnosis, Differential , Female , Humans , Lung Neoplasms/metabolism , Male , Middle Aged , Paraneoplastic Endocrine Syndromes/metabolism , Pregnancy , Pregnancy Complications/blood , Pregnancy Complications/diagnosis
11.
Clin Endocrinol (Oxf) ; 78(4): 533-8, 2013 Apr.
Article in English | MEDLINE | ID: mdl-22583337

ABSTRACT

AIM: To examine the impact of surgical normalization of testosterone on body weight and on glucose and lipid metabolism and insulin sensitivity in a group of hyperandrogenic women with ovarian androgen-secreting tumours (OAST). METHODS: Five consecutive postmenopausal hyperandrogenic patients (aged 63 ± 5 years) with a diagnosis of OAST were prospectively evaluated. Clinical signs, symptoms and metabolic and hormonal parameters were collected at the time of the diagnosis and at follow-up, 12 months after surgical oophorectomy. A group of 15 age-matched and body mass index-matched postmenopausal control women served as a reference group. RESULTS: At baseline, patients with OAST had very high testosterone levels and inappropriately low gonadotrophin levels for their menopausal status. All the women were overweight or obese, and one had a history of polycystic ovary syndrome and Type 2 diabetes. Twelve months after surgical oophorectomy, testosterone and gonadotrophin levels returned to appropriate values for menopausal status in all patients; however, no change in body weight was found. Fasting glucose levels slightly increased (P < 0·05) without any significant change in other metabolic parameters. In the woman with diabetes, a moderate decrease in haemoglobin A1c occurred. Red blood cell count and haematocrit values were normalized (P < 0·05, respectively). CONCLUSION: Normalization of androgen levels achieved after surgical oophorectomy did not cause any significant change in body weight and insulin sensitivity. These findings may offer a different perspective on the impact of hyperandrogenaemia on metabolism.


Subject(s)
Androgens/metabolism , Hyperandrogenism/metabolism , Hyperandrogenism/surgery , Ovarian Neoplasms/surgery , Sertoli-Leydig Cell Tumor/surgery , Aged , Body Weight/physiology , Case-Control Studies , Diabetes Mellitus, Type 2/blood , Diabetes Mellitus, Type 2/complications , Diabetes Mellitus, Type 2/metabolism , Female , Humans , Hyperandrogenism/blood , Hyperandrogenism/etiology , Insulin Resistance , Middle Aged , Obesity/blood , Obesity/complications , Obesity/metabolism , Ovarian Neoplasms/complications , Ovarian Neoplasms/metabolism , Paraneoplastic Endocrine Syndromes/blood , Paraneoplastic Endocrine Syndromes/metabolism , Paraneoplastic Endocrine Syndromes/surgery , Polycystic Ovary Syndrome/blood , Polycystic Ovary Syndrome/complications , Polycystic Ovary Syndrome/metabolism , Postmenopause/blood , Postmenopause/metabolism , Sertoli-Leydig Cell Tumor/complications , Sertoli-Leydig Cell Tumor/metabolism
12.
Fertil Steril ; 94(3): 1097.e9-1097.e12, 2010 Aug.
Article in English | MEDLINE | ID: mdl-20334861

ABSTRACT

OBJECTIVE: To review the diagnostic possibilities that exists when the workup of amenorrhea reveals an isolated LH elevation; and to examine the effect of inhibin B on LH levels in vivo. DESIGN: Case report. SETTING: University hospital. PATIENT(S): A 20-year-old woman presented with secondary amenorrhea. Her FSH measurement was low, and the LH level was elevated. The recognition that this was an unusual pattern led to the diagnosis of a rare but very treatable inhibin B-producing thecoma, despite the fact that results on the initial pelvic ultrasound examination performed 10 months after presentation of amenorrhea were relatively unremarkable. INTERVENTION(S): Surgical removal of an ovarian thecoma. MAIN OUTCOME MEASURE(S): Gonadotropins, E2, inhibin B, menstrual bleeding, and fertility. RESULT(S): Removal of the ovarian thecoma resulted in a normalization of FSH, LH, and inhibin B levels and a return of spontaneous menses 28 days later. Pregnancy occurred with the third postoperative menstrual cycle, followed by the delivery of a healthy full-term girl. CONCLUSION(S): Inhibin B-producing sex cord granolosa-stromal cell tumors should be considered in women who present with amenorrhea with isolated LH elevations, even in the setting of a previously normal pelvic ultrasound report. Diagnostic considerations that arise in the workup of amenorrhea when there is an isolated elevation in LH that is accompanied by normal or low FSH levels are reviewed. This rare clinical presentation provides the opportunity to observe the impact of inhibin B on gonadotropins in vivo.


Subject(s)
Amenorrhea/diagnosis , Inhibins/metabolism , Luteinizing Hormone/metabolism , Ovarian Neoplasms/diagnosis , Thecoma/diagnosis , Amenorrhea/blood , Amenorrhea/etiology , Amenorrhea/metabolism , Female , Humans , Inhibins/physiology , Luteinizing Hormone/blood , Ovarian Neoplasms/complications , Ovarian Neoplasms/metabolism , Paraneoplastic Endocrine Syndromes/complications , Paraneoplastic Endocrine Syndromes/diagnosis , Paraneoplastic Endocrine Syndromes/metabolism , Thecoma/complications , Thecoma/metabolism , Up-Regulation , Young Adult
13.
Hinyokika Kiyo ; 54(4): 289-92, 2008 Apr.
Article in Japanese | MEDLINE | ID: mdl-18516923

ABSTRACT

A 74-year-old man visited our hospital presenting with pollakisuria. Cystoscopy revealed a bladder cancer with necrotic tissue. The patient was initially treated by transurethral resection of bladder tumor (TUR-Bt). Pathologically, the tumor was shown to be a carcinoma of bladder with human chorionic gonadotropin (hCG) positivity. After TUR-Bt, chemotherapy with M-VAC (methotrexate, vinblastine, adriamycine and cisplatin) was performed. This patient is still alive eight months after resection. To our knowledge, there are 37 cases of beta-hCG-producing urothelial carcinoma of the urinary bladder reported in the Japanese literature.


Subject(s)
Carcinoma/metabolism , Chorionic Gonadotropin, beta Subunit, Human/biosynthesis , Paraneoplastic Endocrine Syndromes/metabolism , Urinary Bladder Neoplasms/metabolism , Aged , Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Carcinoma/therapy , Humans , Male , Paraneoplastic Endocrine Syndromes/therapy , Urinary Bladder Neoplasms/therapy
14.
Pituitary ; 10(3): 237-49, 2007.
Article in English | MEDLINE | ID: mdl-17541749

ABSTRACT

We report on three newly diagnosed patients with extracranial ectopic GHRH-associated acromegaly with long-term follow-up after surgery of the primary tumor. One patient with a pancreatic tumor and two parathyroid adenomas was the index case of a large kindred of MEN-I syndrome. The other two patients had a large bronchial carcinoid. The first patient is still in remission now almost 22 years after surgery. In the two other patients GHRH did not normalize completely after surgery and they are now treated with slow-release octreotide. IGF-I normalized in all patients. During medical treatment basal GH secretion remained (slightly) elevated and secretory regularity was decreased in 24 h blood sampling studies. We did not observe development of tachyphylaxis towards the drug or radiological evidence of (growing) metastases. We propose life-long suppressive therapy with somatostatin analogs in cases with persisting elevated serum GHRH concentrations after removal of the primary tumor. Independent parameters of residual disease are elevated basal (nonpulsatile) GH secretion and decreased GH secretory regularity.


Subject(s)
Acromegaly/etiology , Adenoma/metabolism , Carcinoid Tumor/metabolism , Human Growth Hormone/metabolism , Lung Neoplasms/metabolism , Pancreatic Neoplasms/metabolism , Paraneoplastic Endocrine Syndromes/metabolism , Parathyroid Neoplasms/metabolism , Acromegaly/pathology , Adenoma/pathology , Adenoma/surgery , Adult , Carcinoid Tumor/diagnostic imaging , Carcinoid Tumor/surgery , Entropy , Female , Hormones/blood , Humans , Longitudinal Studies , Lung Neoplasms/diagnostic imaging , Lung Neoplasms/surgery , Magnetic Resonance Imaging , Male , Middle Aged , Octreotide , Pancreatic Neoplasms/pathology , Pancreatic Neoplasms/surgery , Paraneoplastic Endocrine Syndromes/pathology , Paraneoplastic Endocrine Syndromes/surgery , Parathyroid Neoplasms/pathology , Parathyroid Neoplasms/surgery , Pituitary Gland/pathology , Positron-Emission Tomography , Tomography, X-Ray Computed , Treatment Outcome
16.
J Clin Endocrinol Metab ; 92(5): 1600-5, 2007 May.
Article in English | MEDLINE | ID: mdl-17299065

ABSTRACT

CONTEXT: Nonpancreatic tumors may cause recurrent hypoglycemia known as nonislet cell tumor hypoglycemia. It is due to overproduction and secretion by the tumor of incompletely processed IGF-II, termed big IGF-II. We recently identified a patient with recurrent hypoglycemia and low insulin, but without elevated big IGF-II. Multiple small lung nodules were detected by computed tomography scan. An undifferentiated large-cell carcinoma was diagnosed from an axillary lymph node metastasis. OBJECTIVE: The objective was to investigate whether the patient's hypoglycemia was due to excessive IGF-I production by the tumor. METHODS: Serum IGF- I and IGF-II, insulin, and GH were measured by RIA; the distribution of IGFs between IGF binding protein complexes in serum was analyzed after neutral gel filtration. Tissue IGF-I was identified by immunohistochemistry and in situ hybridization, and by RT-PCR after RNA extraction. RESULTS: Total and free serum IGF-I, but not total, free, and big IGF-II, was increased, and the IGF-I content of the two IGF binding protein complexes was elevated. Immunohistochemistry demonstrated IGF-I peptide in situ hybridization IGF-I mRNA in the lymph node metastasis. Combined GH/glucocorticoid treatment prevented hypoglycemia, but did not lower IGF-I. After chemotherapy with carboplatinum/etoposide, the lung nodules largely regressed, and serum IGF-I and the IGF-I content of the two binding protein complexes became normal. Hypoglycemia did not recur despite discontinuation of GH/glucocorticoid treatment. CONCLUSION: Our findings are compatible with a new form of tumor hypoglycemia caused by circulating tumor-derived IGF-I.


Subject(s)
Carcinoma, Large Cell/metabolism , Hypoglycemia/etiology , Insulin-Like Growth Factor I/biosynthesis , Lung Neoplasms/metabolism , Paraneoplastic Endocrine Syndromes/metabolism , Antineoplastic Agents/administration & dosage , Antineoplastic Agents, Phytogenic/administration & dosage , Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Blood Glucose/metabolism , Carboplatin/administration & dosage , Carcinoma, Large Cell/drug therapy , Carcinoma, Large Cell/pathology , Chromatography, Gel , Etoposide/administration & dosage , Female , Human Growth Hormone/blood , Humans , Immunohistochemistry , In Situ Hybridization , Insulin/blood , Insulin-Like Growth Factor Binding Proteins/blood , Insulin-Like Growth Factor II/biosynthesis , Lung Neoplasms/drug therapy , Lung Neoplasms/pathology , Lymphatic Metastasis , Middle Aged , RNA/biosynthesis , RNA/genetics , Reverse Transcriptase Polymerase Chain Reaction
18.
An Sist Sanit Navar ; 28(2): 213-26, 2005.
Article in Spanish | MEDLINE | ID: mdl-16155618

ABSTRACT

We can define paraneoplastic syndromes as a combination of effects occurring far from the original location of the tumour and independently from the local repercussion of its metastases. Paraneoplastic hormonal syndromes depend on the secretion of hormonal peptides or their precursors, cytokines and, more rarely, thyroidal hormones and Vitamin D, which act in an endocrine, paracrine or autocrine way. Sometimes, paraneoplastic syndromes can be more serious than the consequences of the primary tumour itself and can precede, develop in parallel, or follow the manifestations of this tumour. It is important to recognise a paraneoplastic hormonal syndrome for several reasons, amongst which we would draw attention to three: 1) It can lead to the diagnosis of a previously undetected, underlying malign or benign neoplasia; 2) It can dominate the clinical picture and thus lead to errors with respect to the origin and type of primary tumour; and 3) It can follow the clinical course of the underlying tumour and thus be useful for monitoring its evolution. The molecular mechanisms responsible for the development of these syndromes are not well-known, but it is believed that they might be inherent to the mutations responsible for the primary tumour or depend on epigenetic factors such as methylation. In this review, we consider the following paraneoplastic hormonal syndromes: malign hypercalcaemia, hyponatraemia (inappropiate secretion of the antidiuretic hormone), ectopic Cushing's syndrome, ectopic acromegaly, hypoglycaemia due to tumours different from those of the islet cells and paraneoplastic gynaecomastia; we make a brief final reference to other hormones (calcitonin, somatostatin, and VIP).


Subject(s)
Paraneoplastic Endocrine Syndromes , ACTH Syndrome, Ectopic/diagnosis , Acromegaly/diagnosis , Acromegaly/etiology , Cushing Syndrome/diagnostic imaging , Diagnosis, Differential , Female , Gynecomastia/diagnosis , Gynecomastia/etiology , Hormones, Ectopic/metabolism , Humans , Hypercalcemia/diagnosis , Hypercalcemia/etiology , Hypoglycemia/etiology , Inappropriate ADH Syndrome/diagnosis , Male , Paraneoplastic Endocrine Syndromes/diagnosis , Paraneoplastic Endocrine Syndromes/metabolism , Radiography, Abdominal , Tomography, X-Ray Computed
20.
Endocr Pract ; 10(2): 125-8, 2004.
Article in English | MEDLINE | ID: mdl-15256329

ABSTRACT

OBJECTIVE: To report a case of recurrent hypercalcemia due to ectopic production of parathyroid hormone (PTH) and parathyroid hormone-related protein (PTH-rP) from transitional cell carcinoma of the urinary bladder. METHODS: We present clinical, laboratory, and pathologic findings in a 73-year-old man with recurrent hypercalcemia. Results of serum calcium, PTH, PTH-rP and immunostaining of tumors for PTH and PTH-rP over 9 years are presented. RESULTS: In 1990 this patient was diagnosed with primary hyperparathyroidism, which was cured by resection of a parathyroid adenoma in the neck. Hypercalcemia recurred in 1992, and he was found to have squamous cell carcinoma of the right lung. PTH-rP levels were not measured, but the resected tumor immunostained positive for the presence of PTH-rP. The patient subsequently remained normocalcemic until 1996, when the plasma calcium and PTH levels increased again. Surgical exploration of the neck revealed no parathyroid adenoma. Elevated plasma levels of calcium and PTH persisted after surgery. In 1998 the patient was diagnosed with stage IV invasive transitional cell carcinoma (TCC) of the urinary bladder and underwent radical cystectomy. The tumor tissue was not immunoreactive to PTH-rP. A year later, plasma levels of PTH and PTH-rP increased, but surgical re-exploration of the neck again revealed no parathyroid adenoma. CT scanning identified a large retroperitoneal mass, and a CT-guided biopsy of the mass showed metastatic, poorly differentiated TCC immunopositive for PTH and PTH-rP. CONCLUSION: This is the first report of ectopic production of PTH from metastatic TCC of the urinary bladder coexisting with PTH-rP mediated hypercalcemia.


Subject(s)
Hypercalcemia/etiology , Neoplasms, Second Primary/complications , Neoplasms/complications , Paraneoplastic Endocrine Syndromes/complications , Paraneoplastic Endocrine Syndromes/metabolism , Parathyroid Hormone-Related Protein/biosynthesis , Parathyroid Hormone/biosynthesis , Adenoma/complications , Aged , Carcinoma, Squamous Cell/complications , Carcinoma, Transitional Cell/complications , Carcinoma, Transitional Cell/pathology , Humans , Lung Neoplasms/complications , Male , Neoplasm Invasiveness , Neoplasm Staging , Parathyroid Neoplasms/complications , Recurrence , Urinary Bladder Neoplasms/complications , Urinary Bladder Neoplasms/pathology
SELECTION OF CITATIONS
SEARCH DETAIL
...